Immune monitoring of patients treated with a whole-cell melanoma vaccine engineered to express 4-1BBL

Keyphrases

• Whole Cell 100%
• 4-1BBL 100%
• Melanoma Vaccine 100%
• Costimulatory Molecules 100%
• Immune Monitoring 100%
• Melanoma 66%
• CD8+ T Cells 66%
• Anti-melanoma 66%
• 4-1BB Ligand 66%
• Cell-based 33%
• Interferon-α (IFN-α) 33%
• Vaccination 33%
• Overall Survival 33%
• Tumor Regression 33%
• Immune Regulation 33%
• Adverse Events 33%
• T Cell Subsets 33%
• Antitumor Activity 33%
• Melanoma Cells 33%
• Antigen-specific 33%
• HLA-A2 33%
• Melanoma Antigens 33%
• American Joint Committee on Cancer 33%
• CD8 Lymphocytes 33%
• CD107a 33%
• Cancer Stage 33%
• Epitope Specificity 33%
• HLA 4 33%
• Anti-tumor Response 33%

Medicine and Dentistry

• Cytotoxic T-Cell 100%
• Patient Monitoring 100%
• CD137 Ligand 100%
• Melanoma Vaccine 100%
• Whole Cell 100%
• CD8 Antigen 50%
• Mediator 50%
• Nodular Melanoma 50%
• Antineoplastic Activity 50%
• Overall Survival 50%
• Melanoma Cell 50%
• Tumor Regression 50%
• Adverse Event 50%
• Antigen Specificity 50%
• T Cell Subset 50%
• Cancer Staging 50%
• Melanoma Cell Line 50%
• Melanoma Antigen 50%
• Lymphocyte 50%
• Cell Line 50%
• Interferon 50%
• Epitope 50%

Immunology and Microbiology

• Cytotoxic T-Cell 100%
• Whole Cell 100%
• Melanoma Vaccine 100%
• CD137 Ligand 100%
• Interferon Type I 50%
• Epitope 50%
• Vaccine Efficacy 50%
• Cell-Based Vaccine 50%
• T Cell Subset 50%
• Lymphocyte 50%
• CD8 50%
• Mediator 50%
• Cell Line 50%
• Antineoplastic Activity 50%
• Overall Survival 50%
• Antigen Specificity 50%
• Melanoma Cell 50%
• Melanoma Antigen 50%
• Melanoma Cell Line 50%
• Vaccination Policy 50%
• Cancer Staging 50%